HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SAMSCA safely and effectively. See full prescribing information for SAMSCA.  SAMSCA (tolvaptan) tablets for oral

First Page		Document Content
Date: 2014-03-04 13:22:36 Medicine Organochlorides Hyponatremia Tolvaptan Central pontine myelinolysis Norfloxacin Chemistry Electrolyte disturbances Organic chemistry		HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SAMSCA safely and effectively. See full prescribing information for SAMSCA.  SAMSCA (tolvaptan) tablets for oral Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 464,78 KB Share Document on Facebook

	DE2300c5:Inhibition of 11b-hydroxysteroid dehydrogenase type 2: as a potential therapeutic treatment for hyponatremia [[[COMMENT BY Developmental Editor]]] The title should be concise ytacrtl ecietemi idnso h td.Ihv,teeo DocID: 1vdco - View Document
	Hyponatremia Hypertension Syndrome With Staphyloma –An Infrequent Cause of Hypertension Vaibhav Agnihotri1, Nagmani Aggarwal3, Ss Majigowdar2 1 Paediatrics, Jjm medical college, India The hyponatremic hypertensive syn DocID: 1uWBO - View Document
	AugustScientific Editing report Paper title: DE2300c5: a potential therapeutic treatment for hyponatremia SUMMARY A prolonged decrease in serum sodium concentration can cause chronic hyponatremia, a condition DocID: 1uAOD - View Document
	DE2300c5:Inhibition of 11b-hydroxysteroid dehydrogenase type 2: as a potential therapeutic treatment for hyponatremia [[[COMMENT BY Developmental Editor]]] The title should be concise ytacrtl ecietemi idnso h td.Ihv,teeo DocID: 1tIY5 - View Document
	DE2300c5:Inhibition of 11b-hydroxysteroid dehydrogenase type 2: as a potential therapeutic treatment for hyponatremia [[[COMMENT BY Developmental Editor]]] The title should be concise ytacrtl ecietemi idnso h td.Ihv,teeo DocID: 1tIT7 - View Document